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Foam cells are specialized lipid-loaded macrophages derived from monocytes and are
a key pathological feature of atherosclerotic lesions. Lysophosphatidylcholine (LPC)
is a major lipid component of the plasma membrane with a broad spectrum of
proinflammatory activities and plays a key role in atherosclerosis. However, the role of
LPC in lipid droplet (LD) biogenesis and the modulation of inflammasome activation is
still poorly understood. In the present study, we investigated whether LPC can induce
foam cell formation through an analysis of LD biogenesis and determined whether
the cell signaling involved in this process is mediated by the inflammasome activation
pathway in human endothelial cells and monocytes. Our results showed that LPC
induced foam cell formation in both types of cells by increasing LD biogenesis via a
NLRP3 inflammasome-dependent pathway. Furthermore, LPC induced pyroptosis in
both cells and the activation of the inflammasome with IL-1β secretion, which was
dependent on potassium efflux and lysosomal damage in human monocytes. The
present study described the IL-1β secretion and foam cell formation triggered by LPC
via an inflammasome-mediated pathway in human monocytes and endothelial cells.
Our results will help improve our understanding of the relationships among LPC, LD
biogenesis, and NLRP3 inflammasome activation in the pathogenesis of atherosclerosis.
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INTRODUCTION
Atherosclerosis is caused by a proinflammatory process (1) mediated by the deposition of excess
lipids in the arterial intima (2), resulting in the development of lesions in the arterial walls. These
atherosclerotic lesions are fibro-fatty plaques in the intima of arteries (3) characterized by abundant
cells with multiple lipid droplets (LDs) in the cytoplasm. Owing to this foamy morphology, these
enhanced LD-containing cells are called foam cells. Foam cells are fundamental components of
the establishment and progression of atherosclerosis and leukocyte recruitment to the site of
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the disease (4). Foam cell formation within the subendothelial
atherosclerotic microenvironment is induced by internalization
of extracellular modified low-density lipoprotein (LDL),
including highly inflammatory oxidized LDL (oxLDL) (5–
7). The major bioactive lipid component of oxLDL is the
phospholipid lysophosphatidylcholine (LPC) (4, 8, 9). This
lipid is thought to be responsible for many of the inflammatory
effects of oxLDL and is reported to increase atherosclerotic
lesions (9–11).
LPC is a bioactive phospholipid generated by various
biological processes, including phospholipase A2 (PLA2)-
catalyzed cleavage of phosphatidylcholine (PC) (12) and
oxidation of LDL. LPC is highly abundant in human blood,
possessing a wide range of proinflammatory activities and an
important role in cellular signaling. Most circulating LPC is
associated with albumin and oxLDL molecules. Owing to this
association, LPC has a major function in atherosclerosis as a
critical factor in oxLDL’s atherogenic activity and induces cellular
cholesterol efflux (13).
As an important immunomodulator molecule, LPC can
induce foam cell formation by promoting LD biogenesis (14),
leukocyte activation and recruitment (15), cytokine secretion
(14–19), and macrophage polarization (20). LDs are important
cellular activation markers that function as key synthesis and
storage sites for cytokine and lipid mediator generation (14).
It was believed that the presence of LDs in cells was only
related to lipid storage and transport. However, LDs are
now known to be highly regulated organelles involved in
many aspects of metabolism and cell activation, including the
inflammatory response (21). The main contents of LDs are
neutral lipids, triacylglycerol, cholesterol ester, phospholipids,
and various proteins, reflecting the lipid uptake by the cells
and its consumption. LD accumulation occurs in different
pathologies, such as obesity, liver steatosis, myopathy, and
atherosclerosis (22).
In addition to LDs, high levels of cholesterol crystals are
found in the cytoplasm of enhanced LD-containing cells or foam
cells (23–26). The formation of cholesterol crystals has been
shown to activate the NLRP3 inflammasome (27), leading to
IL-1β release (28, 29), clearly linking cholesterol metabolism
with innate immune activation. Inflammasomes are intracellular
multiprotein complexes present in activated cells, where they
are responsible for mediating the activation of inflammatory
caspases (30). This protein complex assembly leads to caspase-
1 autoprocessing, which results in the maturation of the
proinflammatory cytokines pro-IL-1β and pro-IL-18 into their
active forms, IL-1β and IL-18. In addition to this process, a
lytic form of cell death known as pyroptosis, characterized by
membrane pore formation, can also be induced (31).
The first signal for inflammasome activation is initiated
through pattern recognition receptor (PRR) signaling, which
can recognize pathogen-associated molecular patterns (PAMPs),
causing NF-κB translocation from the cytoplasm to the nucleus
and promoting the transcription of pro-IL-1β and pro-IL-18.
A second signal, which can be mediated by danger-associated
molecular pattern (DAMP) recognition, is necessary to activate
pro-caspase-1 into its active form, caspase-1. Then, caspase-1 can
cleave pro-IL-1β and pro-IL-18 to their active forms, IL-1β and
IL-18 (32). These second signals include reactive oxygen species
(ROS) production (33), potassium efflux (34), and lysosomal
damage caused by cathepsin B release to the cytoplasm (35).
Dysregulated inflammasome activation has been
deeply associated with the establishment and treatment
of atherosclerosis (36–43). LPC induces the secretion of
proinflammatory cytokines, such as IL-1β (44, 45), TNF-α (46),
and IL-6 (47), but it is still unclear whether LPC can modulate
inflammasome activation and whether this process is involved in
LPC-induced LD biogenesis. Here, we characterized the cellular
and molecular mechanisms involved in the regulation of NLRP3
inflammasome activation and pyroptosis induced by LPC and
investigated the role of this process in LD biogenesis-associated
foam cell formation.
MATERIALS AND METHODS
Culture of THP-1 Cells and Human
Umbilical Vein Endothelial Cells
THP-1, a human monocyte cell lineage, was cultured in
Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich)
supplemented with 10% fetal bovine serum (FBS) (Gibco) and
50µM of 2-mercaptoethanol. Human umbilical vein endothelial
cells (HUVECs), a human endothelial cell lineage, were cultured
in DMEM/F12 (Sigma-Aldrich) supplemented with 10% FBS.
The cells were maintained at 37◦C under a 5% CO2 atmosphere.
Lysophosphatidylcholine Treatment and
Inhibitors
All experiments were conducted using the phospholipid 1-
palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (LysoPC
16:0) from Avanti Polar Lipids. LPC stock was diluted in ethanol
and kept at −20◦C. Before all the assays, LPC was dried with
nitrogen, diluted in culture medium, and sonicated for 10min.
For some experiments, lipopolysaccharide (LPS) (500 ng/ml;
Sigma-Aldrich) and ATP (1mM; Sigma-Aldrich) were used as
positive controls. Depending on the assay, the cells were also
treated with pharmacological inhibitors: N-acetyl-L-cysteine
(NAC), 5mM (Sigma-Aldrich); Ac-YVAD-cho, 20µM (Enzo
Life Sciences); glyburide, 150µM (Sigma-Aldrich); CA074-
ME, 50µM (Sigma-Aldrich); statin, 25µM (Sigma-Aldrich);
GW9662, 1µM (Sigma-Aldrich); methyl-beta-cyclodextrin,
10µM (Sigma-Aldrich); and PAb-hTLR2, 10 µg/ml (InvivoGen).
MTT Assay
MTT assays were performed in THP-1 cells and HUVECs treated
with different concentrations of LPC. The cells were seeded
in a 96-well plate and treated with 0.1, 1, 10, 20, 50, and
100µg/ml of LPC. After 24 h, the medium was replaced with
10% MTT solution (5 mg/ml, Sigma-Aldrich, USA) diluted in
culture medium. The cells were incubated for 4 h at 37◦Cwith 5%
solution, and then the MTT solution was removed and replaced
with 100 µl of DMSO. The plate was further incubated for 5min
at room temperature, and the optical density (OD) of the wells
was determined using a SpectraMax M3 plate reader (Molecular
Devices, USA) at a test wavelength of 570 nm.
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Bodipy Staining and Flow Cytometry
Analysis
THP-1 cells and HUVECs were stained with a fluorescent
lipophilic probe, BODIPY 493/503 (Life Technologies), which
binds with intracellular neutral lipids present in LDs. The probe
was diluted in phosphate-buffered saline (PBS) at 1:5,000 for
30min. At the end of the incubation, the cells were washed with
PBS and centrifuged at 1,500 RPM for 5min at 4◦C; this process
was repeated 3×. The supernatants were discarded, and the cells
were resuspended in 500 µl of PBS. Data from 10,000 events
were acquired on a FACSVerse system (BD Biosciences) and were
analyzed with FlowJo software.
FLICA Staining and Flow Cytometry
Analysis
THP-1 cells and HUVECs were stimulated with 1µg/ml of
LPC or LPS (500 ng/ml) + ATP (1mM) for 1, 3, and 24 h
at 37◦C. After this incubation time, the cells were stained
with the fluorescent inhibitor probe FAM-YVAD-FMK, present
in the FAM FLICA Caspase-1 assay kit (ImmunoChemistry
Technologies, USA), to label active caspase-1 enzyme in living
cells. The probe was added to the medium at 1:30 for 30min.
At the end of the incubation, we recovered the suspension
of cells in a 2-ml Eppendorf tube (Eppendorf Safe-lock tube
2ml, Sigma-Aldrich) and added 1.7ml of 1× Apoptosis Washer
buffer present in the assay kit. The tubes were centrifuged at
1,500 RPM for 2min at room temperature. After centrifugation,
the supernatant was carefully discarded, and then 1ml of 1×
Apoptosis Washer buffer was added. The tubes were centrifuged
again under the same conditions. At the end, the supernatants
were discarded, and the cells were resuspended with 300 µl of
1× Apoptosis Washer buffer. The cells were then analyzed by
flow cytometry (BD FACSCalibur, BD Bioscience) using the FL1-
H channel. The analysis and histogram graphics were performed
using FlowJo software.
Membrane Pore Formation Assay
The kinetics of membrane pore formation in the THP-1 cells
and HUVECs were evaluated by analyzing propidium iodide (PI)
uptake in the stained cells. The cells were seeded in a black, clear-
bottom 96-well plate in a medium without phenol red and 1
mg/ml of PI. Treated cells were incubated at 37◦C, and PI was
excited at 538 nm. The fluorescence emission was read at 617 nm
every 5min using a SpectraMax M3 plate reader (Molecular
Devices, USA).
Microscopy
For confocal microscopy, THP-1 cells and HUVECs were grown
on 12-mm circular glass slides. After incubation with LPC,
the cells were washed and fixed with 4% paraformaldehyde
in phosphate buffer (pH 7.4) (30min, room temperature). For
intracellular cell staining, the cells were permeabilized with 1%
Triton X-100 plus 2% bovine serum albumin (BSA) in PBS. The
cells were stained with anti-HMGB1 antibody (1:400) and Alexa
Fluor 546 (1:2,000) secondary Ab for HMGB1 translocation
analysis or with the BODIPY probe (1:300) for LD biogenesis
analysis. Cellular nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI) (1:5,000). The images were taken using a
Leica TCS SP5 confocal microscope (Leica Microsystems).
Cytokine Measurement
Cytokines in the cell-free supernatants from the THP-1 cells
and HUVECs were detected by enzyme-linked immunosorbent
assays (ELISAs) according to the manufacturer’s instructions
(eBioscience and R&D Systems).
Lactate Dehydrogenase Release
Cell death was determined by measuring lactate dehydrogenase
(LDH) activity in the cell supernatants using a commercial
cytotoxicity assay (CytoTox 96 nonradioactive cytotoxicity assay;
Promega, Madison, WI, USA).
Western Blot Analysis
HUVECs were treated with different concentrations of LPC (1
and 10µg/ml) for 1, 3, and 24 h. The proteins were extracted
using lysis buffer (50mM of Tris-HCl, 150mM of NaCl, 5mM
of EDTA, and 1% Triton X-100) and Cocktail Protease Inhibitor
(04693159001, Roche). The gel contained 12% polyacrylamide,
and the transfer occurred using a semidry system. Themembrane
was blocked for 1 h and incubated overnight at 4◦C with the
following primary antibodies: rabbit recombinant monoclonal
anti-pro Caspase1 + p10 + p12 (ab179515, Abcam), HMGB1
mouse monoclonal antibody (66525-1-Ig, ptglab), anti-IL-1β
(ab2105, Abcam), and anti-GSDMD rabbit monoclonal antibody
([EPR19829], ab210070, Abcam). The membrane was then
incubated for 1 h with a rabbit or mouse secondary antibody
(111-035-006, Jackson ImmunoResearch). The loading control
was an anti-beta actin antibody (A3854, Aldrich). The bands were
revealed using chemiluminescence substrate (Westar Supernova
XLS3L and XLS3P) with an Image Quant LAS 4000 system (GE
Healthcare Life Sciences). The bands were analyzed with ImageJ
software (Version 1.8).
Statistical Analysis
GraphPad Prism 6.0 (GraphPad Software) was used for
the statistical analyses. Multiple group comparisons were
conducted using one-way ANOVA, followed by Tukey’s test




Cell Formation in Human Monocytes Is
Dependent on HMG-CoA Reductase,
PPARγ, and Lipid Rafts
To verify whether LPC could induce foam cell formation in
human monocytes, we treated these cells with 1µg/ml of
LPC for 24 h and analyzed LD biogenesis through confocal
fluorescence microscopy and flow cytometry. LPC treatment
increased LD formation in monocytes compared with those in
untreated control cells, as shown by confocal microscopy images
(Figure 1A). In addition, this result was quantitatively confirmed
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FIGURE 1 | Lysophosphatidylcholine (LPC) induces foam cell formation in human monocytes through mechanisms dependent on HMG-CoA reductase, PPAR-γ, and
lipid rafts. (A) Human monocytes were stimulated with 1µg/ml of LPC, and after 24 h, lipid droplets were stained with the fluorescent probe BODIPY (green), and the
nucleus was labeled with DAPI (blue). Images were taken by confocal microscopy. Scale bar, 25µm. (B) Human monocytes were pretreated with (C) HMG-CoA
reductase inhibitor (statin—Stat.), (D) antagonist of PPAR-γ [GW9662 (GW)], and (E) destabilizer of lipid rafts [methyl-β-cyclodextrin (MBCD)] for 1 h and stimulated
with 1µg/ml of LPC for 24 h. Lipid droplets were stained with BODIPY and analyzed by flow cytometry. Histograms are representatives of three independent
experiments. Each bar graphic represents the mean fluorescence intensity (MFI), and bars show significant differences and represent the 95% confidence interval
(*p < 0.05, **p < 0.01, and ****p < 0.0001) of the cells stimulated with LPC or UNS (unstimulated cells).
by flow cytometric analysis (see Supplementary Figure 1A),
in which LPC induced increased LD biogenesis in human
monocytes (Figure 1B). Furthermore, we investigated the
mechanisms related to lipid metabolism involved in LPC-
induced LD biogenesis. When HMG-CoA reductase, an
important enzyme in cholesterol synthesis, was inhibited,
a significant decrease in LPC-mediated LD production was
observed (Figure 1C). Given that LPC induces PPARγ expression
in macrophages (20), we investigated the role of PPARγ in LPC-
induced LD biogenesis. Our results showed that inhibition of
PPARγ decreases LD biogenesis in human monocytes stimulated
with LPC (Figure 1D). Finally, we studied the role of lipid
rafts in LD biogenesis induced by LPC. Disruption of lipid
rafts induced a decrease in LD biogenesis in human monocytes
stimulated with LPC (Figure 1E). The treatments did not reduce
cell viability (see Supplementary Figure 2A).
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Lysophosphatidylcholine-Induced Foam
Cell Formation in Human Endothelial Cells
Is Dependent on HMG-CoA Reductase,
PPARγ, and Lipids Rafts
Endothelial cells play a critical role in vascular homeostasis
and the development of atherosclerosis (48). Thus, the
mechanisms involved in LPC-induced LD biogenesis were
also investigated in human endothelial cells with the same
experimental design mentioned above using human monocytes.
LPC treatment increased LD formation in human endothelial
cells compared with untreated control cells, as shown by
confocal microscopy images (Figure 2A). In addition, this
result was quantitatively confirmed by flow cytometric analysis
(see Supplementary Figure 1B), in which LPC increased LD
biogenesis in human endothelial cells (Figure 2B). Similarly, for
FIGURE 2 | Lysophosphatidylcholine (LPC) induces foam cell formation in human endothelial cells through mechanisms dependent on HMG-CoA reductase, PPAR-γ,
and lipid rafts. (A) Human endothelial cells were stimulated with 1µg/ml of LPC, and after 24 h, lipid droplets were stained with the fluorescent probe BODIPY (green),
and the nucleus was labeled with DAPI (blue). Images were taken by confocal microscopy. Scale bar, 25µm. (B) Human endothelial cells were pretreated with (C)
inhibitor of HMG-CoA reductase (statin—stat), (D) antagonist of PPAR-γ [GW9662 (GW)], and (E) destabilizer of lipids rafts [methyl-β-cyclodextrin (MBCD)] for 1 h and
stimulated with 1µg/ml of LPC for 24 h. Lipid droplets were stained with BODIPY and analyzed by flow cytometry. Histograms are representatives of three independent
experiments. Each bar graphic represents the mean fluorescence intensity (MFI), and each bar graphic represents the mean fluorescence intensity (MFI), and bars
show significant differences and represent the 95% confidence interval (*p < 0.05 and **p < 0.01) of the cells stimulated with LPC or UNS (unstimulated cells).
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human monocytes, we investigated the mechanisms related to
lipid metabolism involved in the LPC-induced LD biogenesis
in human endothelial cells. When HMG-CoA reductase
(Figure 2C) and PPARγ (Figure 2D) were inhibited and lipid
rafts were disrupted (Figure 2E), we observed a significant
reduction in the LD biogenesis induced by LPC compared with
that of the untreated cells stimulated with LPC that did not show
decreased cell viability (see Supplementary Figure 2B).
Lysophosphatidylcholine-Induced
Caspase-1 Activation and Foam Cell
Formation Is Dependent on Caspase-1
Activation
The activity of the caspase-1 enzyme is critical for the processing
and maturation of the IL-1β cytokine and the promotion of
pyroptosis. Therefore, we investigated whether LPC could induce
the activation of caspase-1. Human monocytes and human
endothelial cells were stimulated with 1µg/ml of LPC for
different times. After the stimulation period, the cells were
labeled with FLICA and analyzed by flow cytometry. The results
demonstrated that LPC induced the activation of caspase-1
from 1 to 24 h in human monocytes (Figure 3A). However, in
human endothelial cells, LPC induced activation of caspase-1
only at 3 h (Figure 3D). To confirm these results, we analyzed
pro-caspase-1 via western blots, and increased expression was
observed in cells stimulated with LPC after 24 h (Figure 3C).
We also investigated the role of caspase-1 activation in foam
cell formation. For this, both cell types were pretreated for 1 h
with a caspase-1 inhibitor (Y-VAD) and stimulated with 1 µg of
LPC for 24 h. After the stimulation period, the cells were labeled
with BODIPY and analyzed by flow cytometry. We observed
a significant decrease in LD biogenesis in the cells pretreated
with the inhibitor of caspase-1 activity, compared with the
untreated cells stimulated with LPC. Therefore, we showed that
LPC-induced foam cell formation was dependent on caspase-1
activity in humanmonocytes (Figure 3B) and human endothelial
cells (Figure 3E).
Lysophosphatidylcholine-Induced IL-1β
Release and Foam Cell Formation Are
Dependent on Lysosomal Damage in
Human Monocytes
Chronic inflammation of the arterial wall is a key element
in the pathogenesis of atherosclerosis. Among the factors that
trigger inflammation, the activation of the inflammasome and
the consequent IL-1β and IL-18 secretion have been increasingly
studied due to their atherogenic capacity (49). We investigated
whether LPC could induce inflammasome activation through
IL-1β release in human monocytes. To accomplish this, we
treated and stimulated THP-1 cells as follows: (I) primed with
500 ng/ml LPS as the first signal of inflammasome activation
and then stimulated with 1µg/ml of LPC as the second signal
of inflammasome activation; (II) stimulated with 1µg/ml of
LPC alone; and (III) stimulated with 1µg/ml of LPC, the first
signal, and treated with 1mM of ATP as the second signal. Our
results demonstrated that treatment with LPC alone induced
a significant increase in IL-1β release in human monocytes.
Moreover, this release was potentiated when the cells were
primed with LPS.We also observed an increase in the IL-1β levels
when LPC acted as a first signal and ATP acted as a second signal
(Figure 4A).
Several mechanisms are associated with inflammasome
activation and IL-1β secretion. To verify which mechanisms are
involved in the secretion of IL-1β and foam cell formation by
LPC, we pretreated human monocytes for 1 h with the following
treatments: (A) TLR2 neutralizing antibody; (B) cathepsin B
inhibitor; (C) Inhibitor of potassium efflux; and (D) ROS
inhibitor. After treatment, the monocytes were stimulated with
1µg/ml of LPC, and∼24 h after the treatments, the supernatants
were collected, and the IL-1β release was measured by ELISAs.
In parallel, the cells were labeled with BODIPY fluorescence
probe, and LD biogenesis was quantitatively analyzed using
flow cytometry. Our results showed that the induction of IL-1β
secretion by LPC is dependent on TLR2 recognition, because
there was a decrease in the IL-1β levels in the cells pretreated with
the TLR2 neutralizing antibody, compared with the untreated
cells stimulated with LPC (Figure 4B).
LPC-induced IL-1β secretion and foam cell formation were
dependent on lysosomal damage because a significant reduction
in IL-1β levels (Figure 4C) and a substantial decrease in LD
biogenesis (Figure 4F) were observed in the cells pretreated with
the cathepsin B inhibitor and stimulated with LPC, compared
with the untreated cells stimulated with LPC (Figure 4C).
Our results also showed that LPC induced LD biogenesis
in an oxidative stress-dependent manner because BODIPY
fluorescence staining decreased in the human monocytes treated
with the ROS inhibitor (NAC) prior to LPC stimulation,
compared with the untreated cells stimulated with LPC
(Figure 4G). However, secretion of IL-1β induced by LPC was
independent of the generation of ROS, because there was no
decrease in IL-1β secretion in the cells pretreated with the ROS
inhibitor, compared with the untreated cells stimulated with LPC
(Figure 4D). When we inhibited the potassium efflux, there was
a significant reduction in the IL-1β levels in the cells treated with
the inhibitor, compared with the cells stimulated with LPC alone
(Figure 4E), thus, IL-1β release induced by LPC is dependent
on potassium efflux. However, there was no difference in the
LD biogenesis in monocytes pretreated with the potassium efflux
inhibitor prior to LPC stimulation and the cells stimulated with
LPC alone, showing that foam cell formation was independent of
potassium efflux in these cells (Figure 4H).
Lysophosphatidylcholine-Induced Foam
Cell Formation Is Dependent on the
Second Signals of Inflammasome
Activation in Human Endothelial Cells
We investigated whether LPC could induce inflammasome
activation through IL-1β release in human endothelial cells,
and the expression of pro-IL-1β in the cells and IL-1β in
the supernatant was evaluated by western blots. LPC did
not induce alterations in the expression levels of pro-IL-1β
and IL-1β (Figure 5A). To confirm the western blot data,
we used the same experimental design mentioned above for
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FIGURE 3 | Lysophosphatidylcholine (LPC) induces activation of caspase-1 and foam cell formation in a caspase-1 activation-dependent manner. (A) Human
monocytes and (D) human endothelial cells were stimulated with 1µg/ml of LPC for 1, 3, and 24 h; the cells were stained with FAM-YVAD-FLICA to determine the
(Continued)
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FIGURE 3 | caspase-1 activity and analyzed by flow cytometry. In addition, (C) the protein levels of pro-caspase-1 was examined by western blot analysis. Beta actin
was used as an internal control. (B) Human monocytes and (E) human endothelial cells were pretreated with a caspase-1 inhibitor (Y-VAD) for 1 h and stimulated with
1µg/ml of LPC for 24 h. Lipid droplets were stained with BODIPY and analyzed by flow cytometry. Histograms are representatives of three independent experiments.
Each bar graphic represents the mean fluorescence intensity (MFI), and each bar graphic represents the mean fluorescence intensity (MFI), and bars show significant
differences and represent the 95% confidence interval (*p < 0.05) of the cells stimulated with LPC or UNS (unstimulated cells).
monocytes for human endothelial cells. In contrast to the
results in human monocytes, LPC did not induce IL-1β release
in human endothelial cells (Figure 5B). In addition, our data
demonstrated that LPC significantly induced the secretion of
TNF-α compared to that of the unstimulated (UNS) control
group of human endothelial cells (Supplementary Figure 3A)
and human monocytes (Supplementary Figure 3C). The same
proinflammatory effect was observed when LPC significantly
induced IL-6 secretion compared with that in the UNS group of
human endothelial cells (Supplementary Figure 3B) and human
monocytes (Supplementary Figure 3D).
The mechanisms involved in LPC-induced LD biogenesis
were also investigated in human endothelial cells with the same
experimental design mentioned above. When we inhibited the
release of cathepsin B, a substantial decrease in LPC-induced
LD biogenesis was observed compared with that of LPC-only
UNS cells (Figure 5C). Our results showed that LPC induced
LD biogenesis in an oxidative stress-dependent manner. When
we inhibited ROS production, a decrease in LPC-induced LD
biogenesis was detected compared with that of LPC-only UNS
cells (Figure 5D). However, unlike monocytes, when endothelial
cells were treated with potassium efflux inhibitor, there was a
significant decrease in LD biogenesis compared with that of cells
stimulated with LPC alone, showing that the biogenesis of LD in
endothelial cells is dependent on potassium efflux (Figure 5E).
Pyroptosis Is Induced by
Lysophosphatidylcholine in Human
Monocytes and Endothelial Cells
To verify whether LPC triggers an inflammatory form of cell
death, pyroptosis, we evaluated membrane pore formation in
humanmonocytes and endothelial cells after treatment with LPC
at two different concentrations. We found that only cells treated
with 20µg/ml of LPC exhibited an increase in membrane pore
formation in human endothelial cells (Figure 6A) in the early
hours of stimulation. This result corroborated the cell viability
analysis and LDH release, where LPC significantly decreased
cell viability at a concentration of 20µg/ml (Figure 6C) and
increased LDH release at 10µg/ml (Figure 6E).
In humanmonocytes, treatment with LPC inducedmembrane
pore formation at different concentrations and stimulation times.
When we used the lowest concentration of LPC (10µg/ml),
membrane pore formation occurred ∼7 h after treatment.
However, when we used the highest concentration of LPC
(20µg/ml), membrane pore formation occurred within the first
few hours of treatment (Figure 6B). This result was consistent
with the cell viability analysis, where LPC at a concentration of
10µg/ml significantly decreased cell viability after 24 h in human
monocytes (Figure 6D). In addition, LPC at a concentration of
1µg/ml increased LDH release after 24 h in human monocytes
(Figure 6F).
HMGB1 is a high mobility, non-histone protein with a
structural role in the chromosome architecture that is generally
found in the nucleus. During inflammation, cellular activation,
and cell death, these proteins translocate into the cytoplasm and
are a marker of pyroptosis. In addition, the translocation of
HMGB1 to the cytoplasm occurs after the activation of caspase-1
by different inflammasomes, leading to its subsequent secretion.
After being secreted by cells of the immune system, HMGB1
functions as a DAMP, triggering an inflammatory response in
several cells, leading to death by pyroptosis (50, 51). We also
investigated whether LPC treatment in human monocytes and
endothelial cells affected the translocation of HMGB1 to the
cytoplasm. Our results showed that LPC (10µg/ml) induced the
translocation of HMGB1 to the cytoplasm in both endothelial
cells (Figure 6G) and monocytes (Figure 6H). In addition,
HMGB1 release and cleaved gasdermin D were detected by
western blots. LPC increased HMGB1 release (Figure 6I) and
gasdermin D cleavage in a dose-dependent manner in human
endothelial cells (Figure 6J). These data confirmed that LPC
induces pyroptosis in these cells.
DISCUSSION
Endothelial cells have an important role in the progression
of atherosclerosis because they secrete chemokines and other
substances that attract monocytes to the site of atherogenic
development, in addition to overexpressing adhesion molecules
that facilitate diapedesis (52–54). Circulating monocytes and
resident macrophages are also fundamental cells in the
development of atherosclerosis. These cells can phagocytize
oxLDL molecules and cholesterol, storing these contents in
cytoplasmic LDs, which are key organelles for cellular lipid
metabolism, triggering differentiation of these cells into foam
cells (55, 56). In this context, our data showed for the first
time that endothelial cells can differentiate into foam cells after
treatment with LPC, increasing the amount of LDs in their
cytoplasm. Our results also confirmed that LPC can trigger an
increase in LD biogenesis in human monocytes, leading to foam
cell formation.
During the formation of foam cells, there is a large efflux
of cholesterol and oxLDL that are stored in LDs. HMG-
CoA reductase is an enzyme located in hepatic tissue that
produces mevalonate, a small molecule used in the synthesis
of cholesterol and other mevalonate derivatives, and is the
target of drugs of the statin class used to lower cholesterol
levels (57). Given the importance of cholesterol during the
establishment and development of atherosclerosis, we decided
to investigate the role of this enzyme in the LD biogenesis
induced by LPC. Our data also showed that when HMG-
CoA reductase is inhibited, LPC-induced LD biogenesis in
monocytes and endothelial cells is decreased, corroborating
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FIGURE 4 | Lysophosphatidylcholine (LPC) induces IL-1β release and foam cell formation mediated by an inflammasome-dependent pathway in human monocytes.
Human monocytes (A) were pretreated with LPS (500 ng/ml) 4 h before treatment with 1 µg of LPC for 24 h. After this treatment, the cells were treated with ATP
(1mM). One hour later, the supernatants were collected, and the levels of IL-1β were measured by ELISAs. Data are expressed as the average of triplicate wells. In
addition, human monocytes were pretreated with different inhibitors: (B) TLR2 neutralizing antibody (α-TLR2), (C) cathepsin B inhibitor (CA-074), (D) reactive oxygen
species (ROS) inhibitor [N-acetyl-L-cysteine (NAC)], and (E) inhibitor of potassium efflux [glibenclamide (GLY)] for 1 h and stimulated with 1µg/ml of LPC for 24 h; the
supernatants were collected, and the levels of IL-1β were measured by ELISAs. The bar graph represents one experiment performed twice in triplicate. Human
monocytes were pretreated with different inhibitors (F) cathepsin B inhibitor (CA-074), (G) reactive oxygen species (ROS) inhibitor [N-acetyl-L-cysteine (NAC)], and (H)
inhibitor of potassium efflux [glibenclamide (GLY)] for 1 h and stimulated with 1µg/ml of LPC for 24 h, the lipid droplets were stained in cells with BODIPY and analyzed
by flow cytometry. Histograms are representative of three independent experiments. Each bar graphic represents the mean fluorescence intensity (MFI), and bars
show significant differences and represent the 95% confidence interval (*p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.0001) of the cells stimulated with LPC or
UNS (unstimulated cells).
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FIGURE 5 | Lysophosphatidylcholine (LPC) induces foam cell formation mediated by an inflammasome-dependent pathway in human endothelial cells. Human
endothelial cells were stimulated with 1 and 10µg/ml of LPC. After 24 h, the protein levels of (A) pro–IL-1β and IL-1β in the supernatants or cell lysates were examined
by western blot analysis. Beta actin was used as an internal control. Human endothelial cells (B) were pretreated with LPS (500 ng/ml) 4 h before treatment with 1 µg
of LPC for 24 h. After this time, the cells were treated with ATP (1mM). One hour later, the supernatants were collected, and the levels of IL-1β were measured by
ELISAs. The bar graph represents one experiment performed twice in triplicate. In addition, human endothelial cells were pretreated with different inhibitors: (C)
cathepsin B inhibitor (CA-074), (D) reactive oxygen species (ROS) inhibitor (N-acetyl-L-cysteine [NAC]), and (E) inhibitor of potassium efflux [glibenclamide (GLY)] for
1 h and stimulated with 1 µg of LPC for 24 h. Lipid droplets were stained with BODIPY and analyzed by flow cytometry. Histograms are representatives of three
independent experiments. Each bar graphic represents the mean fluorescence intensity (MFI), and bars show significant differences and represent the 95%
confidence interval (*p < 0.05) of the cells stimulated with LPC or UNS (unstimulated cells).
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FIGURE 6 | Lysophosphatidylcholine (LPC)-induced pyroptosis in human monocytes and human endothelial cells. (A) Human endothelial cells and (B) human
monocytes were stimulated with 10 and 20µg/ml of LPC. Pore formation was assessed fluorometrically in real time by the uptake of propidium iodide [relative
fluorescence units (RFUs)]. The line represents one experiment performed twice in quintuplicate. (C) Human endothelial cells and (D) human monocytes were
(Continued)
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FIGURE 6 | stimulated with different concentrations of LPC. Twenty-four hours later, the cells were incubated with MTT to evaluate the cytotoxicity. (E) Human
endothelial cells and (F) human monocytes were stimulated with 1, 10, and 20µg/ml of LPC. After 24 h, the LDH release was quantified. The bar graphs represent
one experiment performed three times in triplicate. Each bar shows a significant difference and represents a confidence interval of 95% (*p < 0.05, **p < 0.01, ***p <
0.005, and ****p < 0.0001) with the unstimulated control. (G) Human endothelial cells and (H) human monocytes were stimulated with 10µg/ml of LPC. After 18 h,
the cells were stained with anti-HMGB1 conjugated with Alexa 546 and labeled with DAPI to visualize the nuclei. Images were taken by confocal microscopy. UNS:
unstimulated cells. Bright field images were used as a morphology control. Scale bar, 25 and 10µm. Human endothelial cells were stimulated with 1 and 10µg/ml of
LPC. After 24 h, the protein levels of (I) HMGB1 and (J) cleavage of GSDMD were examined by western blot analyses. Beta actin was used as an internal control.
FIGURE 7 | Model proposed for lysophosphatidylcholine (LPC)-mediated inflammasome activation and foam cell formation in human monocytes and endothelial cells.
LPC plays a major role in the establishment and progression of atherosclerosis. LPC can increase the lipid droplets in macrophages and endothelial cells and promote
inflammation through the activation of the NLRP3 Inflammasome. In addition, LPC can induce cell death by pyroptosis through the translocation of HMGB1 from the
nucleus to the cytoplasm and pore formation.
the importance of cholesterol synthesis in LPC-induced foam
cell formation.
PPARs play a key role in the regulation of cell differentiation,
development, and lipid metabolism (58). The expression of
PPARγ in macrophages is closely related to atherosclerosis. Using
a murine model, Tontonoz and colleagues showed that PPARγ
was highly expressed in the nucleus of foam cells isolated from
atherosclerotic lesions (59). Therefore, we investigated the role
of PPARγ in LPC-induced LD biogenesis. Our results showed
that inhibition of PPARγ decreased LD biogenesis in both
monocytes and endothelial cells. Our data are consistent with
those described by Hou et al. in which LPC promotes cholesterol
efflux in fat cells in a mechanism dependent on the activation
pathway of PPARγ and LXFα associated with apoE (60).
In foam cells, cholesterol crystals can trigger NLRP3
inflammasome activation, leading to IL-1β release. Recently,
Freeman et al. showed that LPC-induced IL-1β secretion in
BMDMs is dependent on NLRC4, NLRP3, caspase-1, and ASC,
whereas the non-canonical inflammasome-associated protein
caspase-11 is not involved. In addition, LPC could induce
NLRC4 and NLRP3 inflammasome activation in microglia
and astrocytes in a caspase-1 activation-dependent manner
(61, 62). LPC can induce IL-1β release in human monocytes
(45). However, the mechanisms involved in this process have
not yet been fully elucidated. The present work showed
that LPC can induce IL-1β secretion by acting either as
a first or second signal during inflammasome activation in
human monocytes. This result corroborates the findings that
electronegative LDL induces IL-1β secretion as a first or
second signal for NLRP3 activation (63). Despite this result,
we did not observe LPC-induced IL-1β secretion in human
endothelial cells.
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We also investigated the role of caspase-1 in LD biogenesis.
Both the monocyte and endothelial cell results showed that when
caspase-1 is inhibited, a decrease in LD formation induced by
LPC is observed. In addition, our results showed a relationship
between NLRP3 inflammasome activation pathways and foam
cell formation. When the NLRP3 inflammasome is activated, it
can promote the release of IL-1β and the induction of foam cell
formation (64). Here, we verified that LD biogenesis is dependent
on caspase-1 activation.
TLR2 is involved in the recognition of LPC (14, 65).
Here, we showed that this recognition is essential for LPC-
induced IL-1β secretion in human monocytes. The role of LPC-
induced oxidative stress, through ROS generation, is already
known (66). Here, we found that foam cell formation in
both cells is dependent on ROS generation. However, the
same signaling pathway did not mediate IL-1β secretion in
human monocytes. Liu and colleagues demonstrated that oxLDL
induces IL-1β secretion and foam cell formation through
CD36, ROS generation, and NLRP3 activation (49). Our data
corroborated this previous role of ROS generation in foam cell
development. In addition, we demonstrated for the first time
the mechanisms involved in foam cell formation in endothelial
cells. By evaluating the role of other signals present during
inflammasome activation, we demonstrated that IL-1β release,
after treatment with LPC in human monocytes, is dependent
on lysosomal damage and potassium efflux. These findings
support the data from Stock et al., which demonstrated that
blockage of potassium channels reduced the levels of IL-1β after
treatment with LPC in microglia (44), and Liu et al. showed
that blocking the release of cathepsin B decreased oxLDL-
induced IL-1β secretion in monocytes (49). Analysis of the
formation of foam cells showed that LPC-induced biogenesis
is also dependent on potassium efflux and lysosomal damage
in human endothelial cells. However, in human monocytes,
this process was only dependent on lysosomal damage and was
independent of potassium efflux. Consequently, we detected a
direct relationship between NLRP3 inflammasome activation
and IL-1β release in triggering LD biogenesis and foam
cell formation.
Chang and colleagues demonstrated that LPC induces
cytotoxicity/apoptosis and IL-8 production in human
endothelial cells via mechanisms dependent on ROS,
ATM/Chk2, ATR/Chk2, and PI3K/Akt signaling (67).
Pyroptosis is a form of proinflammatory cell death and
(68) can be mediated by inflammasome-dependent caspase-1
activation (69) or caspase-11 (70), which is responsible for
the cleavage and/or maturation of gasdermin D (GSDMD)
and membrane pore formation (71), IL-1β (72), IL-18 (73),
HMGB1 (74), and LDH release (75). Pyroptosis has been
shown to play important roles in cardiovascular diseases,
such as atherosclerosis (76). In this work, we showed that
LPC could induce pyroptosis in monocytes and endothelial
cells owing to the increase in membrane pore formation and
LDH released after treatment with high concentrations of
LPC. These results agree with data shown by Lopez-Pastrana
and colleagues, where LPC triggered pyroptosis of endothelial
cells in a caspase-1-dependent manner in an ischemia model
(77). However, we also identified the role of the HMGB1
protein in this LPC-induced pyroptosis of monocytes and
endothelial cells.
Taken together, these results demonstrated that LPC
can induce foam cell formation through LD biogenesis
in human endothelial cells and human monocytes in an
inflammasome-dependent pathway, as summarized in the
graphical abstract (Figure 7). In addition, LPC induces the
secretion of IL-1β in human monocytes but not in human
endothelial cells. Surprisingly, LPC can induce pyroptotic
cell death in human monocytes and human endothelial
cells, and this process may be involved in the maintenance
of the inflammation observed in the tissues adjacent to
vascular regions and the pathology of atherosclerosis.
Therefore, in the present work, we characterized different
cellular and molecular mechanisms involved in foam
cell formation and the creation of a microenvironment
favorable for the establishment and maintenance of
atherosclerotic plaques.
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